0.932
-0.03 (-3.33%)
| Penutupan Terdahulu | 0.964 |
| Jumlah Dagangan | 487,765 |
| Harga / Buku (P/B) | 2.39 |
| Julat 52 Minggu |
| EPS Cair (TTM) | -0.110 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 2.69% |
| Nisbah Semasa (MRQ) | 1.02 |
| Aliran Tunai Operasi (OCF TTM) | -1.53 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -8.99 M |
| Pulangan Atas Aset (ROA TTM) | -84.13% |
| Pulangan Atas Ekuiti (ROE TTM) | -250.49% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Tiziana Life Sciences Ltd | Bercampur | Bercampur |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Purata | -0.36 |
|
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 43.06% |
| % Dimiliki oleh Institusi | 2.73% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Mid-American Wealth Advisory Group, Inc. | 30 Jun 2026 | 323,240 |
| Zhang Financial Llc | 30 Jun 2026 | 125,950 |
| Rachor Investment Advisory Services, Llc | 30 Jun 2026 | 17,000 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |